{"organizations": [], "uuid": "06c056bf5047b05cce20310879cc8ca055686269", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-selecta-biosciences-presents-new-d/brief-selecta-biosciences-presents-new-data-from-ongoing-phase-2-trial-of-sel-212-in-development-for-chronic-severe-gout-idUSFWN1RN0MC", "country": "US", "domain_rank": 408, "title": "BRIEF-Selecta Biosciences Presents New Data From Ongoing Phase 2 Trial Of Sel 212 In Development For Chronic Severe Gout", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T15:41:00.000+03:00", "replies_count": 0, "uuid": "06c056bf5047b05cce20310879cc8ca055686269"}, "author": "", "url": "https://www.reuters.com/article/brief-selecta-biosciences-presents-new-d/brief-selecta-biosciences-presents-new-data-from-ongoing-phase-2-trial-of-sel-212-in-development-for-chronic-severe-gout-idUSFWN1RN0MC", "ord_in_thread": 0, "title": "BRIEF-Selecta Biosciences Presents New Data From Ongoing Phase 2 Trial Of Sel 212 In Development For Chronic Severe Gout", "locations": [], "entities": {"persons": [], "locations": [{"name": "panlar", "sentiment": "none"}], "organizations": [{"name": "brief-selecta biosciences", "sentiment": "negative"}, {"name": "selecta biosciences inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "development for chronic severe gout reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News  42 PM / Updated 12 minutes ago BRIEF-Selecta Biosciences Presents New Data From Ongoing Phase 2 Trial Of Sel 212 In Development For Chronic Severe Gout Reuters Staff \nApril 10 (Reuters) - Selecta Biosciences Inc: \n* 212, IN DEVELOPMENT FOR CHRONIC SEVERE GOUT, AT PANLAR 2018 CONGRESS \n* 212 PRODUCT PROFILE MAY PROVIDE BETTER AND MORE SUSTAINED SERUM URIC ACID CONTROL \n* 212 GENERALLY WELL TOLERATED AT CLINICALLY ACTIVE DOSES FOLLOWING REPEATED ADMINISTRATIONS IN ONGOING PHASE 2 TRIAL \n* 212 IS EXPECTED TO START LATER IN 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-10T15:41:00.000+03:00", "crawled": "2018-04-10T16:00:39.000+03:00", "highlightTitle": ""}